Concepedia

Author

Karen So

AstraZeneca (United Kingdom)

Also Known As

Alexandra Mattinson, K. So, Karen B. E. So, Karen So

54

Publications

1.4K

Citations

19

H-Index

45

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)IQVIA (United States)University of ManchesterAstraZeneca (Singapore)
KS

About

Karen So is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

550

2

Engineering

2

2

40

3

Biochemistry

1

1

10

4

Biomedical Engineering

1

1

28

5

Computer Science

1

1

12

Karen So

×

30

Publications

1.3K

Citations

18

H-Index

YearCitations

Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies

Mark W. J. Ferguson, Jonathan Duncan, Jeremy S. Bond,

The Lancet

2009

296

Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial

Karen So, Duncan Angus McGrouther, James Bush,

Plastic & Reconstructive Surgery

2011

111

Interleukin‐10 reduces scar formation in both animal and human cutaneous wounds: Results of two preclinical and phase <scp>II</scp> randomized control studies

Ingrid Kieran, Amanda Knock, James Bush,

Wound Repair and Regeneration

2013

110

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karthick Vishwanathan, Paul A. Dickinson, Karen So,

British Journal of Clinical Pharmacology

2018

73

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Alan L. Ho, Marek Dedecjus, Lori J. Wirth,

Journal of Clinical Oncology

2022

59

Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial

James Bush, Jonathan Duncan, Jeremy S. Bond,

Plastic & Reconstructive Surgery

2010

56

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Luc Dirix, Helen Swaisland, Henk M.W. Verheul,

Clinical Therapeutics

2016

56

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

Karthick Vishwanathan, Paul A. Dickinson, Khanh Bui,

The Journal of Clinical Pharmacology

2017

54

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

Ruth Plummer, Helen Swaisland, Karin Leunen,

Cancer Chemotherapy and Pharmacology

2015

51

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Christian Rolfo, Helen Swaisland, Karin Leunen,

Advances in Therapy

2015

44

Page 1